

Rec'd PCT/PTO 22 DEC 2005

PATENT #8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HO-YOUNG LEE

Serial No.: 10/531,140

Filed: APRIL 11, 2004

For: **DEGUELIN AS A CHEMOPREVENTIVE
AGENT FOR LUNG CANCER**

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:762US

EXPRESS MAIL MAILING LABEL

NUMBER EV 414840672 US

DATE OF DEPOSIT December 22, 2005

INFORMATION DISCLOSURE STATEMENT

MS PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:762US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 22, 2005

Form PTO-1449 (modified)		Atty. Docket No. UTSC:762US	Serial No. 10/531,140
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ho-Young Lee	
		Filing Date: April 11, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Brognard <i>et al.</i> , "Akt/protein kinase B is constitutively active in non small cel lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation," <i>Cancer Res.</i> , 61:3986-3997, 2001.
	C2	Chang <i>et al.</i> , "Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-Kinase," <i>Science</i> , 276_1848-1850, 1997.
	C3	Di Cristofano <i>et al.</i> , "The multiple roles of PTEN in tumor suppression," <i>Cell</i> , 100:387-390, 2000.
	C4	Gerhäuser <i>et al.</i> , "Rotenoids as cancer chemopreventive agents: investigation of mode of action," <i>Am. Chem. Soc. Abstr.</i> , 211(1-2):81, 1996.
	C5	Gerhäuser <i>et al.</i> , "Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase," <i>Nat. Med.</i> , 1:260-266, 1995.
	C6	Jimenez <i>et al.</i> , "Identification and characterization of a new oncogene d the regulatory subunit of phosphoinositide 3-kinase," <i>EMBO J</i> , 17:743-753, 1998.
	C7	Kinzler <i>et al.</i> , "Lessons from hereditary colorectal cancer," <i>Cell</i> , 97:159-150, 1996.
	C8	Klippel <i>et al.</i> , "Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation," <i>Mol. Cell Biol.</i> 18:5699-5711, 1998.

25552696.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:762US	Serial No. 10/531,140
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ho-Young Lee	
		Filing Date: April 11, 2005	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Lee <i>et al.</i> , "Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells," <i>Clinical Cancer Research</i> , 10:1074-1079, 2004.
	C10	Lee <i>et al.</i> , "Effects of 9-cis-Retinoic acid on the insulin-like growth factor axis in former smokers," <i>J. of Clin. Oncology</i> , 23:4439-4449, 2005.
	C11	Lee <i>et al.</i> , "Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependant pathways cooperate to maintain lung cancer cell survival," <i>J. of Biol. Chem.</i> , 278:23630-23638, 2003.
	C12	Lee <i>et al.</i> , "Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer," <i>Clin. Cancer Res.</i> , 11:6065-6074, 2005.
	C13	Lee, "Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells," <i>Biochemical Pharmacology</i> , 68:1119-1124, 2004.
	C14	Luyengi <i>et al.</i> , "Rotenoids and chalcones from <i>Mundulea sericea</i> that inhibit phorbol ester-induced ornithine decarboxylase activity," <i>Phytochem</i> , 36:1523-1526, 1994.
	C15	Robinson <i>et al.</i> , "Mitogen-activated protein kinase pathways," <i>Curr. Opin. Cell Biol.</i> , 9:180-186, 1997.
	C16	Rodriguez-Viciana <i>et al.</i> , "Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by ras," <i>Cell</i> , 89:457-467, 1997.
	C17	Rowlands and Casida, "Rotenoids inhibit signal transduction pathways which regulate ornithine decarboxylase activity in MCF-7 human breast cancer cells," <i>The Toxicol.</i> , 36:235, 1997.
	C18	Shayesteh <i>et al.</i> , "PIK3CA is implicated as an oncogene in ovarian cancer," <i>Nat. Genet.</i> , 21:99-102, 1999.
	C19	Song and Endow, "Decoupling of nucleotide and microtubule-binding sites in a kinesin mutant," <i>Nature</i> , 396:587, 1998.
	C20	Toker <i>et al.</i> , "Signalling through the lipid products of phosphoinositide-3-OH kinase," <i>Nature</i> , 387:673-676, 1997.
	C21	Tsao <i>et al.</i> , "Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies," <i>Cancer Epidemiology, Biomarkers & Prevention</i> , 12:660-664, 2003.

25552696.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:762US	Serial No. 10/531,140
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Ho-Young Lee	
		Filing Date: April 11, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Vanhaesbrock <i>et al.</i> , "Phosphoinositide 3-kinases: a conserved family of signal transducers," <i>Trends Biochem. Sci.</i> , 22:267-272, 1997.
	C23	Vlahos <i>et al.</i> , "A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), 1994.
	C24	Yano <i>et al.</i> , "Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway," <i>Nature</i> , 396:584-587, 1998.

25552696.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.